Terms: = Ovarian cancer AND HER1, YOR227W AND Treatment
12 results:
1. NRF2 Regulates her1 Signaling Pathway to Modulate the Sensitivity of ovarian cancer Cells to Lapatinib and Erlotinib.
Kankia IH; Khalil HS; Langdon SP; Moult PR; Bown JL; Deeni YY
Oxid Med Cell Longev; 2017; 2017():1864578. PubMed ID: 29410730
[TBL] [Abstract] [Full Text] [Related]
2. An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Wang Z; Fu S
Expert Opin Investig Drugs; 2016; 25(1):15-30. PubMed ID: 26560712
[TBL] [Abstract] [Full Text] [Related]
3. PET imaging of her1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
[TBL] [Abstract] [Full Text] [Related]
4. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
[TBL] [Abstract] [Full Text] [Related]
5. Protein levels and gene expressions of the epidermal growth factor receptors, her1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract] [Full Text] [Related]
6. treatment of premenopausal women with early breast cancer: old challenges and new opportunities.
Aebi S; Pagani O
Drugs; 2007; 67(10):1393-401. PubMed ID: 17600388
[TBL] [Abstract] [Full Text] [Related]
7. [Molecular diagnostic and targeted therapy--"Barking dogs are going to bite": presentations from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta 2006].
Rody A; Loibl S; Kaufmann M
Zentralbl Gynakol; 2006 Oct; 128(5):233-41. PubMed ID: 17001557
[TBL] [Abstract] [Full Text] [Related]
8. ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study.
Leibl S; Bodo K; Gogg-Kammerer M; Hrzenjak A; Petru E; Winter R; Denk H; Moinfar F
Gynecol Oncol; 2006 Apr; 101(1):18-23. PubMed ID: 16330088
[TBL] [Abstract] [Full Text] [Related]
9. Emerging drugs for ovarian cancer.
Kelland LR
Expert Opin Emerg Drugs; 2005 May; 10(2):413-24. PubMed ID: 15934876
[TBL] [Abstract] [Full Text] [Related]
10. Monoclonal antibody therapy of ovarian cancer.
Nicodemus CF; Berek JS
Expert Rev Anticancer Ther; 2005 Feb; 5(1):87-96. PubMed ID: 15757441
[TBL] [Abstract] [Full Text] [Related]
11. Enhanced sensitivity to the her1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract] [Full Text] [Related]
12. Can rash associated with her1/EGFR inhibition be used as a marker of treatment outcome?
Pérez-Soler R
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):23-8. PubMed ID: 14682120
[TBL] [Abstract] [Full Text] [Related]
